TRYP Stock Overview
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Tryp Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.06 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.01 |
| Beta | -1.28 |
| 1 Month Change | 140.00% |
| 3 Month Change | 50.00% |
| 1 Year Change | -25.00% |
| 3 Year Change | -92.77% |
| 5 Year Change | n/a |
| Change since IPO | -91.55% |
Recent News & Updates
Shareholder Returns
| TRYP | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -7.7% | 8.8% | -0.5% |
| 1Y | -25.0% | 64.2% | 5.3% |
Return vs Industry: TRYP underperformed the Canadian Pharmaceuticals industry which returned 64.2% over the past year.
Return vs Market: TRYP underperformed the Canadian Market which returned 5.3% over the past year.
Price Volatility
| TRYP volatility | |
|---|---|
| TRYP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 15.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: TRYP's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TRYP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Jason Carroll | www.tryptherapeutics.com |
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company’s program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications.
Tryp Therapeutics Inc. Fundamentals Summary
| TRYP fundamental statistics | |
|---|---|
| Market cap | CA$5.79m |
| Earnings (TTM) | -CA$2.95m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs TRYP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRYP income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.95m |
| Earnings | -CA$2.95m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -90.5% |
How did TRYP perform over the long term?
See historical performance and comparison